antibody-drug conjugate

ArriVent BioPharma wins FDA clearance for ARR-002, a first-in-class dual-target ADC targeting ovarian and endometrial cancers, with Phase 1 trials expected in H2 2026.

Biolojic Design presents preclinical data for BD200, a dual-target cancer drug showing superior efficacy against resistant tumors. Clinical trials expected in H2 2026.

Zymeworks presents six ADC program updates at AACR 2026, including Phase 1 ZW191 clinical data and novel RAS-targeting platform preclinical results.

Gilead acquires Tubulis for $3.15 billion including milestones, adding HER2-targeting ovarian cancer candidate to oncology pipeline—second major deal in months.

Zymeworks secures FDA Fast Track designation for ZW191, an ovarian cancer antibody-drug conjugate, accelerating development timelines.

Ipsen presents preclinical data for two first-in-class cancer candidates targeting solid tumors and gastrointestinal cancers, advancing its immuno-oncology pipeline.

ALX Oncology reduced losses and secured $150M in funding, extending cash runway to mid-2028. The company advances its clinical pipeline with CD47 biomarker validation for its cancer therapies.